BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Dec 12, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Glivec imatinib regulatory update

The U.K.'s NICE issued a preliminary appraisal recommending the use of Tasigna nilotinib and 400 mg Glivec imatinib, both BCR-ABL tyrosine kinase inhibitors from Novartis, as first-line treatment for chronic myelogenous leukemia (CML). The committee recommended against the use of Sprycel dasatinib from Bristol-Myers Squibb Co. (NYSE:BMY, New...

Read the full 246 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >